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In chronic in¯ammatory conditions, mononuclear
cells in®ltrate the connective tissue attracted by
®broblast-secreted chemokines. The role of ®bro-
blasts in sustaining the lymphocyte immune response
upon cellular in®ltration is so far unresolved. We
here report that, upon prolonged stimulation with
tumor necrosis factor-a, dermal ®broblasts enhance
proliferation of activated T cells whereas unstimu-
lated ®broblasts do not. T cell growth stimulation
requires cell contact of tumor necrosis factor-a
stimulated ®broblasts to T cells and is not due to
soluble factors. Growth stimulation is substantially
blocked by neutralizing antibodies to interleukin-15.
Fluorescence-activated cell sorter analyses revealed
that tumor necrosis factor a stimulated ®broblasts
expose interleukin-15 in a membrane-bound form
on the cell surface whereas nonstimulated ®broblasts
and interferon-g treated ®broblasts do not. The
amount of membrane interleukin-15 increases with
the duration of tumor necrosis factor-a stimulation
for at least 3 d. Unstimulated ®broblasts, however,
accumulate interleukin-15 in the cytoplasm. No
interleukin-15 could be detected in the culture super-
natant. Immunohistochemical analyses con®rmed
membrane interleukin-15 on dermal ®broblasts in
discoid lupus erythematosus skin lesions whereas no
membrane interleukin-15 was found on the surface
of ®broblasts in healthy skin. We conclude that
dermal ®broblasts upon long-term tumor necrosis
factor-a stimulation during chronic in¯ammation
are involved via membrane-bound interleukin-15 in
stimulating proliferation of accumulated, activated T
cells. Key words: cell-to-cell interactions/human ®bro-
blasts/in¯ammation. J Invest Dermatol 116:102±109, 2001
C
hronic in¯ammation is characterized by accumula-
tion of mononuclear cells, i.e., lymphocytes and
monocytes, in the connective tissue. The in¯amma-
tory process is driven by a complex series of
interactions between cells, the extracellular matrix,
and secreted factors of various cell types. In¯ammatory processes,
although triggered by a variety of events, are largely driven by the
expression of cytokines and their receptors by in®ltrating as well as
resident cells of the tissue. Upon migration across vascular
endothelium, leukocytes reach the extravascular space and interact
with connective tissue cells such as ®broblasts as well as with
extracellular matrix proteins such as ®bronectin, laminin, and
collagen. Leucocyte±®broblast interactions are mediated by a panel
of speci®c adhesion molecules induced by proin¯ammatory
cytokines on both leukocytes and ®broblasts (Cabanas and Hogg,
1991; Morzycki and Issekutz, 1991; Bombara et al, 1993; Meng et al,
1995). Interleukin-1 (IL-1) and transforming growth factor-a
(TGF-a) act synergistically to elicit a number of phenotypic
responses in dermal ®broblasts, including proliferation, which are
thought to contribute to chronic in¯ammation (Unemori et al,
1994). Tumor necrosis factor-a (TNF-a), a potent mediator of
in¯ammatory functions, induces ®broblasts to express matrix
metalloproteinases, chemokines, including RANTES (Sticherling
et al, 1995) and eotaxin (Bartels et al, 1996), and adhesion
molecules, e.g., ICAM-1 and VCAM-1 (for review see Barker,
1995). Lymphocytes are attracted by secreted chemokines and
adhere to TNF-a-stimulated ®broblasts within the in¯ammatory
lesion via LFA-1 and VLA-4. Numerous actions of TNF-a,
however, occur in combination with other cytokines within a
cytokine network as part of a cascade of in¯ammatory factors.
Whereas the mechanisms of retention of mononuclear cells at
sites of chronic in¯ammation by adhesion to ®broblasts are more
and more solved, the role of ®broblasts in sustaining proliferation of
attracted, activated leukocytes is poorly understood. This process is
potentially important because the cytokine crosstalk of mono-
nuclear cells and dermal ®broblasts probably contributes to the
chronicity of in¯ammatory skin diseases. We asked whether dermal
®broblasts upon chronic in¯ammatory stimulation are involved in
sustaining proliferation of activated T cells. We here report that
upon prolonged incubation with TNF-a human dermal ®broblasts
stimulate proliferation of activated T cells. The growth-promoting
activity of TNF-a-treated ®broblasts requires cell-cell contact and
is substantially blocked by neutralizing antibodies to IL-15. We
demonstrate that TNF-a-treated ®broblasts express membrane-
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bound IL-15 on the cell surface whereas unstimulated ®broblasts do
not. Biopsies from chronic in¯ammatory lesions con®rm mem-
brane expression of IL-15 of ®broblasts within the lesion whereas
®broblasts in healthy skin do not express membrane IL-15. Growth
stimulation of activated T cells by membrane IL-15 exposed on
®broblasts in chronic in¯ammatory lesions implies a crucial role of
TNF-a-stimulated ®broblasts not only in cell attraction but
moreover in sustaining proliferation of attracted, activated T cells.
MATERIALS AND METHODS
Cytokines, cells, and cell lines Human recombinant interferon-g
(IFN-g) and TNF-a were purchased from R&D Systems (Wiesbaden,
Germany). Fibroblasts were isolated from skin biopsies of healthy donors
and grown in Dulbecco's modi®ed Eagle's medium, 10% (vol/vol) fetal
bovine serum, 50 mg per ml sodium ascorbate, and 300 mg per ml glutamine.
Monocytes and peripheral blood mononuclear cells (PBMC) were puri®ed
from peripheral blood by Percoll gradient centrifugation according to
standard procedures. The purity of the monocyte preparations used in this
study was 90% 6 4% as assessed by morphology of Giemsa-stained
preparations. T cells were isolated from PBMC by nylon wool adherence
(purity of T cells 98% 6 2% CD3+ as assessed by ¯ow cytometry). Jurkat is
a T leukemia line (obtained from ATCC; ATCC TIB 152), HuT102 is a T
cell line (obtained from ATCC; ATCC TIB162), HL60 is a human
promyeloid cell line (obtained from DZM; DSM ACC3), and U937 is a
monoblastoid cell line (obtained from ATCC; ATCC CRL-1593.2). All
cells were cultured in RPMI 1640 medium (Life Technologies, Karlsruhe,
Germany) containing 100 U per ml penicillin, 100 mg per ml streptomycin,
2 mM L-glutamine, and 10% (vol/vol) heat-inactivated fetal bovine serum
(Life Technologies).
Proliferation assay Human ®broblasts were seeded at 5 3 104 cells per
well in 200 ml RPMI 1640 medium in a microtiter plate. [3H]TdR
incorporation assays were performed in triplicate. T cells were seeded at
5 3 104 cells per well, [3H]TdR was added (37 kBq [3H]TdR per well) for
16 h, and proliferation was assessed by b-scintillation spectroscopy.
Flow cytometric analysis To monitor membrane-bound IL-15, cells
were washed twice in phosphate-buffered saline (PBS), incubated in PBS,
2% (vol/vol) rabbit serum for 30 min at 4°C, washed in PBS, 1% (wt/vol)
bovine serum albumin (BSA), and incubated with the mouse antihuman
IL-15 antibody (clone M112; IgG2b; Genzyme, Wiesbaden, Germany) or
an isotype-matched control antibody (IgG2b; Becton Dickinson,
Heidelberg, Germany), respectively, for 30 min at 4°C. Essentially the
same data were obtained when using anti-IL-15 monoclonal antibody
(clone 34505.11) (Preprotech, Rocky Hill) for monitoring IL-15. To
monitor cytoplasmic IL-15, cell membranes were permeabilized by
incubation with PermeaFix (1:2 dilution; Ortho, Raritan, NJ) prior to
antibody incubation. Cells were washed twice in PBS, 1% (wt/vol) BSA,
and incubated with the rabbit phycoerythrin-conjugated antimouse
antibody (Dako, Hamburg, Germany) for 30 min at 4°C. To monitor
IL-15 receptor a-chain, cells were incubated with the goat antihuman IL-
15 Ra antibody (R&D Systems). Cells were analyzed by ¯ow cytometry
utilizing an EPICS XL (Beckman-Coulter, Krefeld, Germany) equipped
with WinMDI software. Human monocytes and Jurkat cells served as
positive and negative controls, respectively. Statistical analysis was
performed by z test (*p < 0.001).
Western blot analysis Fibroblasts were lyzed in the presence of 1%
(vol/vol) Nonidet-P40, 3 mM MgCl2, 10 mM ethylenediamine tetraacetic
acid (EDTA), 50 mM Tris-HCl, pH 7.5, and the protein lysate was
electrophoretically separated through a 12.5% polyacrylamide gel and
blotted onto nitrocellulose. Loading of equal amounts of protein was
recorded by Ponceau S staining of the membrane. Western blot analysis was
performed according to standard methods utilizing rabbit antihuman IL-15
antiserum (BioSource International, Camarillo, CA), swine peroxidase-
labeled antirabbit Ig (Dako), and the ECL detection system (Amersham
Pharmacia Biotech, Freiburg, Germany).
IL-15 enzyme-linked immunosorbent assay (ELISA) Super-
natants from con¯uent ®broblast cultures (106 cells per ml supernatant)
were ®ltered through a 0.22 mm ®lter (Millipore, Molsheim, France) and
assayed for human IL-15 by ELISA (BioSource International; assay
sensitivity 11 pg IL-15 per ml). Alternatively, the supernatant was 10-fold
concentrated using a Centricon Concentrator (Amicon, Beverley, MA)
prior to ELISA testing. To monitor intracellular IL-15, ®broblasts were
lyzed (106 cells in 1 ml) by repeated freezing and thawing in the presence of
3 mM MgCl2, 10 mM EDTA, 50 mM Tris-HCl, pH 7.5. Nuclei and cellular
debris were sedimented and the supernatant was subjected to IL-15 ELISA.
Reverse transcription polymerase chain reaction (RT-PCR)
analysis RNA was puri®ed utilizing High Pure RNA Isolation Kit
(Roche Diagnostics, Mannheim, Germany), cDNA was synthesized
according to standard procedures, and a cDNA aliquot (5 ml) was
ampli®ed in a 50 ml PCR sample. As control, each sample was subjected
to PCR ampli®cation of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA. The following oligonucleotides were used as primers
in PCR reactions (Onu et al, 1997): IL-15 SSP, 5¢ATGGTATT-
GGGAACCATAGA3¢; IL-15 LSP, 5¢ATGAGAATTTCGAAACCA-
CAT3¢; IL-15 MP, 5¢CTCCAAGAGAAAGCACTTC3¢ (cycling
conditions: 1 min 94°C, 1 min 55°C, and 1 min 72°C; 40 cycles);
GAPDH sense, 5¢GGTCGGAGTCAACGGATTTG3¢; and GAPDH
antisense 5¢ATGAGCCCCAGCCTTCTCCAT3¢ (cycling conditions:
1 min 94°C, 1 min 60°C, and 1 min 72°C; 35 cycles).
Immunohistochemistry Membrane-bound IL-15 within cells of a skin
biopsy was monitored using the following staining technique. One half of a
fresh punch biopsy (4 mm in diameter) was incubated overnight at 4°C in
PBS containing anti-IL-15 monoclonal antibody M112 (Genzyme) (1 mg
per ml); the other half of the biopsy was incubated in PBS containing mouse
IgG2b (Becton Dickinson) as isotype control. Non-binding antibody was
washed out by incubating in PBS, 1% (wt/vol) BSA for 1 h at 37°C.
Biopsies were subsequently snap frozen in liquid nitrogen, processed for
cryostat sections, and stained according to standard techniques. Bound
antibody within the section was detected by incubation with a biotin-
labeled goat antimouse F(ab¢)2 antibody (Dako) for 30 min at room
temperature. Subsequently the section was incubated with an avidin-
biotin-peroxidase complex for 30 min at room temperature, washed, and
the staining reaction was developed using 3-amino-9-ethylcarbazol and
H2O2. Nuclei were stained with Mayer's hematoxylin.
RESULTS
We explored whether normal human skin ®broblasts after
prolonged stimulation with TNF-a stimulate proliferation of T
cells in vitro. Therefore, ®broblasts were incubated with TNF-a
(20 ng per ml) for 72 h, thoroughly washed, and subsequently
coincubated with ConA preactivated, CD3+ T cells. Induction of
lymphocyte proliferation was tested by [3H]TdR incorporation. As
summarized in Fig 1(A), ®broblasts preincubated with TNF-a
stimulated proliferation of coincubated T cells whereas untreated
®broblasts did not. Coincubation of TNF-a-pretreated ®broblasts
in Transwell plates without cell contact to T cells did not stimulate
lymphocyte proliferation nor did the ®broblast supernatant (data
not shown). This indicates that the lymphocyte stimulatory activity
of TNF-a-pretreated ®broblasts requires cell contact with
lymphocytes. Preactivated but not unstimulated CD3+ T cells
were induced to proliferate upon contact with TNF-a-treated
®broblasts (data not shown). The effect is speci®c and not due to
residual contamination with TNF-a because the supernatant did
not stimulate proliferation of T cells. We conclude that, upon
stimulation with TNF-a, dermal ®broblasts enhance proliferation
of activated T lymphocytes by cell-to-cell contact.
To identify the ®broblast surface molecule responsible for
increasing T cell proliferation, we incubated TNF-a-stimulated
®broblasts with neutralizing antibodies to various cytokines prior to
coincubation with activated T cells. As summarized in Fig 1(A),
lymphocyte proliferation is substantially, although not completely,
repressed upon blocking with a neutralizing antibody to IL-15
(10 mg per ml) whereas an isotype-matched antibody is ineffective.
This indicates that the growth stimulatory effect of TNF-a-treated
®broblasts is substantially due to IL-15. In contrast, unstimulated
®broblasts did not signi®cantly increase T cell proliferation
(Fig 1A). As controls, T cell proliferation in the absence of
®broblasts was stimulated by recombinant IL-15 and blocked by
addition of the neutralizing antibody to IL-15 but not by addition
of an isotype-matched antibody (Fig 1B). Taken together, the data
imply that TNF-a-treated ®broblasts stimulate proliferation of
activated lymphocytes by cell-to-cell contact by a process that
involves IL-15 exposed on the cell surface of stimulated ®broblasts.
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To monitor expression of membrane-bound IL-15, ®broblasts
were cultured for 72 h in the presence of TNF-a (20 ng per ml)
and, as control, with IFN-g (2000 U per ml), respectively, and
analyzed by ¯uorescence-activated cell sorter (FACS) analysis
utilizing the anti-IL-15 antibody M112. Staining of nonperme-
abilized cells revealed IL-15 on the surface of TNF-a-stimulated
®broblasts but not on the surface of unstimulated or IFN-g-
incubated ®broblasts (Fig 2A). Monocyte cells, which constitu-
tively express membrane-bound IL-15 (Musso et al, 1999), were
used as positive controls and Jurkat cells as negative controls for
monitoring IL-15 (Fig 2B, C). Essentially the same data were
obtained using anti-IL-15 monoclonal antibody clone 34505.11
(Preprotech). IFN-g used in the assay is functionally active because
incubation of ®broblasts with IFN-g (2000 U per ml) induced
ICAM-1 expression (data not shown). Time course analyses
indicate that prolonged incubation with TNF-a gradually increases
IL-15 expression on the surface of ®broblasts during an incubation
time as long as 72 h (Fig 3). In unstimulated ®broblasts, we detected
IL-15 after permeabilization but not without permeabilization of
the cell membrane (Fig 2A). This indicates that IL-15 is
constitutively expressed in unstimulated ®broblasts and stored in
the cytoplasm. Upon TNF-a stimulation, however, IL-15 is
additionally exposed on the cell surface of ®broblasts. As controls,
membrane IL-15 was recorded in monocytes but not in Jurkat cells
in accordance with previous reports (Musso et al, 1999).
Dermal ®broblasts express IL-15 receptor a-chain, the expression
of which is 3-fold increased after stimulation with TNF-a (20 ng
per ml, 72 h) (data not shown). Human endothelial cells were used as
positive controls,HL60cells as negative controls in theFACSanalysis.
Membrane IL-15 on the surface of TNF-a-stimulated ®broblasts,
however, did not elute on treatment with acetate (pH 4.4, 10 min
incubation) suggesting that IL-15 is expressed as an integral
membrane protein and is not associated with the IL-15 receptor
complex. This property is in accordance with membrane IL-15
exposed on the surface of monocytes (Musso et al, 1999).
ELISA tests of cellular lysates con®rmed expression of IL-15 in
unstimulated ®broblasts. Fibroblasts treated with various concen-
trations of TNF-a (2±200 ng per ml) for 72 h express nearly similar
amounts of IL-15 as unstimulated ®broblasts (Fig 4). This
observation was con®rmed by Western blot analysis of cellular
lysates of unstimulated and TNF-a-stimulated ®broblasts, and, as
control, of IFN-g-stimulated ®broblasts (Fig 5). Western blot
analysis moreover revealed that IL-15 in dermal ®broblasts is
expressed in two isoforms, i.e., with an apparent molecular mass of
14 kDa and 16 kDa, respectively. Because IL-15 has two potential
N-glycosylation sites, the two IL-15 isoforms are likely to present
two different glycosylation patterns as recently reported (Gaggero
et al, 1999). No IL-15 was detected in the culture supernatant
conditioned by proliferating ®broblasts during 2 d of culture in vitro
with and without TNF-a stimulation (2±200 ng per ml) (detection
limit of the ELISA is 11 pg IL-15 per ml) (Fig 4). Even in ®broblast
culture supernatants that had been concentrated about 10-fold, no
detectable amounts of IL-15 were monitored. As controls and
consistent with previous reports (Satoh et al, 1998), IL-15 was
detected in the supernatant of HuT102 cells but not in the
supernatant of K562 cells.
We assayed dermal ®broblasts for expression of IL-15-speci®c
mRNA by RT-PCR techniques utilizing primer oligonucleotides
speci®c for the short and the long leader peptide isoform,
respectively (Onu et al, 1997). As shown in Fig 6, both isoforms
of IL-15 RNA were found to be expressed in unstimulated and in
TNF-a (20 ng per ml) stimulated ®broblasts. Monocytes served as
positive control and HL60 cells as negative control of the assay.
Taken together, we conclude that proliferating dermal ®broblasts
in vitro synthesize and store IL-15 intracellularly without secretion
of detectable amounts of IL-15 into the supernatant. After
prolonged incubation with TNF-a, ®broblasts expose IL-15 on
the cell surface that is functionally active in stimulating proliferation
of activated, but not of nonactivated, CD3+ T cells. These
observations imply a functional role of dermal ®broblasts in
sustaining proliferation of accumulated T cells during chronic
in¯ammatory diseases.
We therefore asked whether ®broblasts in chronic in¯amma-
tory lesions expose membrane-bound IL-15. Tissue samples
derived from discoid lupus erythematosus skin lesions and, as
control, from healthy skin were stained in toto with the anti-IL-
15 antibody M112 as described in Materials and Methods.
Cryostat sections were subsequently obtained, stained with an
antimouse F(ab)2 antibody, and visualized by peroxidase
reaction. Incubation of biopsies in toto with the primary
antibody prior to making thin sections allows preferential
staining of membrane-bound molecules within a tissue speci-
men. As shown exemplarily in Fig 7, ®broblasts within lesions
expose IL-15 on the cell membrane whereas ®broblasts in
healthy skin do not. In accordance with previous reports
(Agostini et al, 1996; Musso et al, 1999), monocytes within the
same section show membrane staining with the IL-15 antibody.
Staining is speci®c as an isotype control antibody does not stain
®broblasts or monocytes. This analysis exemplarily demonstrates
that ®broblasts in chronic in¯ammatory conditions in vivo
expose membrane-bound IL-15 whereas dermal ®broblasts in
healthy skin do not. Taken together the data suggest the model
that ®broblasts upon TNF-a stimulation in in¯ammatory skin
Figure 1. Fibroblasts stimulate proliferation of activated T cells. (A)
Dermal ®broblasts were seeded in microwell plates (5 3 104 cells per well)
and cultured without stimulation (h) or with TNF-a stimulation (20 ng
per ml) for 96 h (j). Subsequently, cells were arrested by incubation with
mitomycin C (100 mg per ml, 30 min), washed, and CD3+ T cells
preactivated with ConA (10 mg per ml, 72 h) were added (5 3 104 cells
per well). In addition, antihuman IL-15 antibody (BioSource) (10 mg
per ml) or rabbit IgG (10 mg per ml), respectively, was added. As control,
®broblasts were cultured without T cells (medium). Incorporation of
[3H]TdR was monitored after 72 h of coculture. The dotted line indicates
[3H]TdR incorporation of T cells without cocultured ®broblasts. (B)
CD3+ T cells were prestimulated with ConA (10 mg per ml, 72 h) and
subsequently plated in microwell plates (5 3 104 cells per well). Cells were
incubated without additives or with human recombinant IL-15 (10 ng
per ml), rIL-15 plus antihuman IL-15 antibody (BioSource) (10 mg per ml),
or rIL-15 plus rabbit IgG (10 mg per ml), respectively. After 72 h,
incorporation of [3H]TdR was monitored. Data represent the means
(6 SEM) of triplicates.
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lesions expose membrane-bound IL-15 that is capable of
stimulating proliferation of in®ltrating, activated T cells.
DISCUSSION
An in¯ammatory process can be initiated by a variety of events that
are followed by cell migration, extracellular matrix degradation,
and extensive activation and proliferation of in®ltrating mono-
nuclear cells. These processes are believed to be driven by the
expression of cytokines and their receptors by in®ltrating macro-
phages and lymphocytes and by resident stromal cells. Here we
demonstrate that, upon prolonged incubation with TNF-a, dermal
®broblasts stimulate proliferation of activated T cells by cell-cell
contact. A ®broblast-secreted factor seems not to be involved in this
process because the conditioned culture supernatant is ineffective in
the assay. The growth-promoting activity towards activated T cells
can be partially blocked by addition of a neutralizing antibody to
IL-15 (Fig 1A). The inability of the anti-IL-15 antibody to block
the growth-promoting activity completely may be due to
additional T cell stimulatory molecules expressed in increased
amounts on the surface of TNF-a-treated ®broblasts compared
with unstimulated ®broblasts, e.g., ICAM-1 or VLA-4. Taken
together, the data suggest that IL-15 is localized on cell membranes
of TNF-a-treated ®broblasts. FACS analysis con®rmed expression
of IL-15 on the cell surface of TNF-a-stimulated ®broblasts
(Fig 2A) whereas nonstimulated and IFN-g-treated ®broblasts do
not expose IL-15 on the cell membrane. Because membrane IL-15
is not eluted at pH 4.4, we conclude that IL-15 is exposed as an
integral membrane protein on the surface of TNF-a-stimulated
®broblasts and is not associated with the IL-15 receptor. Expression
on the cell surface assigns IL-15 to the family of cytokines with
membrane-bound activities, as for example TGF-a, TNF-a, IL-1,
and IL-10 (Kurt-Jones et al, 1985; Luettig et al, 1989; Noso et al,
1998; Musso et al, 1999). The same conclusion was recently drawn
from the analysis of membrane IL-15 in monocytes (Musso et al,
1999). Expression of membrane IL-15 on ®broblasts, however,
Figure 2. Dermal ®broblasts express IL-15 on
the cell surface after TNF-a stimulation. Der-
mal ®broblasts were grown in medium or incub-
ated with TNF-a (20 ng per ml) or IFN-g
(2000 U per ml), respectively, for 72 h. Cells were
analyzed nonpermeabilized (non-perm.) or after
permeabilization (perm.) as described in Materials
and Methods. Cells were stained with the anti-IL-
15 monoclonal antibody M112 (closed histograms)
or as control with an isotype-matched control
antibody (IgG2b) (open histograms) and subjected to
FACS analysis. Nonpermeabilized cells indicate
expression of IL-15 on the cell surface, perme-
abilized cells indicate the total amount of IL-15
expression, i.e., intracellular plus membrane IL-15.
Jurkat cells (IL-15±) and monocytes (IL-15+)
served as controls. Monocytes constitutively
express membrane IL-15 as reported (Musso et al,
1999). Essentially the same data were obtained
using anti-IL-15 monoclonal antibody (clone
34505.11) (Preprotech). IFN-g used in this assay is
functionally active because it induces ICAM-1 ex-
pression on ®broblasts (data not shown).
VOL. 116, NO. 1 JANUARY 2001 MEMBRANE IL-15 ON FIBROBLASTS 105
differs from that on monocytes because unstimulated ®broblasts, in
contrast to monocytes, do not express detectable amounts of IL-15
on the cell surface (cf. Fig 2). Induction of membrane IL-15 in
dermal ®broblasts by stimulation with TNF-a is speci®c because
IFN-g did not induce membrane IL-15. This is in contrast to
monocytes, which constitutively express membrane-bound IL-15
in substantial amounts that are furthermore increased by stimulation
with IFN-g (Musso et al, 1999).
The conditioned supernatant of TNF-a-stimulated ®broblasts
did not stimulate proliferation of activated T cells. This is in
accordance with our observation that TNF-a-stimulated
®broblasts do not secrete IL-15 in detectable amounts into
the culture medium as monitored by ELISA (Fig 4).
Unstimulated ®broblasts, however, store intracellular IL-15 that
can be monitored by FACS analysis of permeabilized cells and
by Western blot analysis and ELISA of ®broblast lysates.
Because IL-15 is present in cellular lysates and detectable in
permeabilized cells by FACS, we conclude that unstimulated
dermal ®broblasts constitutively synthesize IL-15 that is stored
intracellularly and not secreted in detectable amounts. This
conclusion is in contrast to the result of the RT-PCR analysis
indicating the long leader IL-15 mRNA isoform suggested to
code for the secreted form of IL-15 (Onu et al, 1997; Tagaya
et al, 1997; Kurys et al, 2000). Recent results, however, assign
differential roles to the IL-15 mRNA isoforms (Kurys et al,
2000; Nishimura et al, 2000); their role in human ®broblasts,
however, remains to be elucidated. Lack of IL-15 secretion by
normal dermal ®broblasts moreover stands in contrast to
Figure 3. Time course of the induction of membrane IL-15 on the surface of ®broblasts after TNF-a stimulation. (A) Dermal ®broblasts were
grown in vitro without TNF-a for 72 h or incubated with TNF-a (20 ng per ml) for 24 h, 48 h, or 72 h, respectively, washed with PBS, and subjected to
FACS analysis of membrane IL-15 utilizing anti-IL-15 monoclonal antibody M112 (closed histograms) or as control an isotype-matched control antibody
(IgG2b) (open histograms). (B) Jurkat cells (IL-15±), U937 cells (membrane IL-15+), and monocytes (membrane IL-15+) served as controls.
Figure 4. Dermal ®broblasts express IL-15 protein. Fibroblasts were
cultured in vitro (106 cells per ml medium) without stimulation or with
incubation with TNF-a (2±200 ng per ml) for 72 h. Cytoplasmic lysates
(h) from unstimulated and TNF-a-stimulated ®broblasts (106 cells in 1 ml
lysis buffer) and the corresponding culture supernatants (1 ml medium
conditioned by 106 cells) (j) were subjected to IL-15-speci®c ELISA.
Detection limit of the ELISA is 11 pg IL-15 per ml.
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®broblast-like synoviocytes from rheumatoid arthritis specimens
that were recently reported to secrete IL-15 (Harada et al,
1999). On the other hand, a variety of cells of different cell
type and tissue origin express IL-15 mRNA, including placenta,
skeletal muscle, kidney, lung, heart, and keratinocytes
(Waldmann and Tagaya, 1999); none of these cells secretes
detectable amounts of IL-15 into the culture supernatant.
Continuous TNF-a stimulation of dermal ®broblasts for
prolonged time, i.e., up to 72 h, gradually increases the amount
of membrane IL-15 exposed on the cell surface, whereas short-term
stimulation is less effective (Fig 3). The time kinetic of induction of
membrane IL-15 is unexpected for TNF-a-induced processes,
which unusually require less than 24 h. We speculate that the
extended time needed to induce membrane IL-15 indicates either a
delayed mechanism of IL-15 translocation from cytoplasmic stores
to the cell membrane or an indirect stimulation pathway by
mediators initially induced by TNF-a. A similarly delayed
mechanism in dermal ®broblasts was reported for TNF-a-initiated
secretion of eotaxin, an eosinophil-chemotactic protein (Noso et al,
1998). It is tempting to speculate that the delayed response of
®broblasts to TNF-a stimulation may be of biologic signi®cance,
particularly in the context of chronic versus acute in¯ammatory
diseases, in order to initiate the cascade of in¯ammatory reactions
preferentially upon prolonged, but not after short-term stimulation
with TNF-a. In accordance with this model, prolonged exposure
to TNF-a induces IL-15 expression in various tissues, i.e., in
alveolar macrophages of patients with active sarcoidosis (Agostini
et al, 1996), in ®broblast-like synoviocytes from patients with
rheumatoid arthitis (Harada et al, 1999), in keratinocytes under
chronic in¯ammatory conditions (Reinecker et al, 1996; Han et al,
1999), and in active hypertrophic scars (Castagnoli et al, 1999).
Only the analysis of Agostini et al (1996), however, discriminates
between IL-15 accumulated in cytoplasmic stores and IL-15
expressed in a membrane-bound form on the cell surface.
IL-15 on the cell membrane of stimulated ®broblasts is
functionally active in enhancing proliferation of activated T cells.
Within the in¯ammatory lesion, membrane-bound IL-15 is likely
to act as a powerful and cooperative multiplier in the local T cell
response upon prolonged TNF-a stimulation. Accordingly, IL-15
is reported to induce proin¯ammatory and antifungal activities in
phagocytic cells (Musso et al, 1998) or chemokines and their
receptors in T cells (Perera et al, 1999). Within the cellular
architecture of the skin, IL-15 exposed on the surface of stimulated
®broblasts may play a unique role in the maintenance of particular
interepithelial and intraepidermal lymphocyte pools in the absence
of antigen and in the survival and expansion of these cells upon
speci®c antigen stimulation. In agreement with this model, Lai et al
(1999) recently reported that IL-15 promotes survival of CD8+
TCRab+ intraepithelial lymphocytes. IL-15-mediated stimulation
of lymphocytes upon viral infections (Seder et al, 1995), the
induction of natural killer cell activation (Fawaz et al, 1999), and the
exposition of membrane IL-15 on the surface of ®broblasts after
prolonged TNF-a stimulation may in concert represent an
important effector mechanism against infections and a potent
mediator of local in¯ammatory reactions.
We draw the model that dermal ®broblasts under chronic
in¯ammatory conditions, such as discoid lupus erythematosus, are
substantially involved in at least three pathophysiologically essential
mechanisms: (i) attraction of activated lymphocytes by secreted
chemokines, e.g., RANTES and eotaxin that are induced by
TNF-a (Sticherling et al, 1995; Bartels et al, 1996); (ii) adherence of
lymphocytes via the LFA-1/ICAM-1 pathway (Cabanas and
Hogg, 1991) that is upregulated by TNF-a and IFN-g (Rothlein
et al, 1991), or via the VLA-4/VCAM-1 pathway that is
upregulated by TNF-a and IL-1 (Gao and Issekutz, 1996); and
(iii) stimulation of proliferation of activated T cells via membrane
IL-15 as shown in this study. The evidence implies that IL-15
plays an important role in these processes, in particular because IL-
15 acts as a potent chemoattractant for T cells, natural killer cells,
and neutrophils (Wilkinson and Liew, 1995; McInnes et al, 1996;
Perera et al, 1999) and, moreover, induces monocytes and
polymorphonuclear cells to secrete proin¯ammatory and chemo-
tactic cytokines (Musso et al, 1998). Accordingly, abnormalities in
IL-15 expression were found in patients with in¯ammatory
autoimmune diseases, such as rheumatoid arthritis, in¯ammatory
bowel disease, and psoriatic arthritis (Reinecker et al, 1996;
McInnes et al, 1997; Perera et al, 1999; Danning et al, 2000). IL-15
activates proin¯ammatory and antimicrobial functions in poly-
morphonuclear blood cells suggesting that IL-15 may additionally
play a crucial role in the activation of phagocytic cells against
pathogens (Musso et al, 1998).
Figure 6. RT-PCR analysis of IL-15 RNA. Dermal ®broblasts were
cultured in vitro (lane 1) or stimulated with TNF-a (20 ng per ml) (lane 2)
for 72 h. cDNA was derived from these cells and subjected to PCR
utilizing primer oligonucleotides speci®c for IL-15 RNA with the short-
signal peptide (SSP) and long-signal peptide (LSP), respectively. As
controls, cDNA from HL60 cells (IL-15±) (lane 3) and monocytes (IL-
15+) (lane 4), respectively, were analyzed for IL-15 RNA expression.
Moreover, cDNA speci®c for GAPDH was ampli®ed in each sample. PCR
products were separated by electrophoresis through a 2% agarose gel.
Figure 5. Western blot analysis of IL-15 expression. Dermal ®broblasts
were mock-treated (lane 1), stimulated with TNF-a (20 ng per ml) (lane 2),
or treated with IFN-g (2000 U per ml) for 72 h. Total cell lysates were
obtained by treatment with Nonidet P-40 (1% vol/vol), subjected to
sodium dodecyl sulfate polyacrylamide gel electrophoresis (about 10 mg
protein per lane), blotted onto Nylon membrane, and probed with rabbit
anti-human IL-15 antiserum (Biosource).
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